ER in Disease

1. Cystic Fibrosis & the Folding Problem

CFTR is a 1480-residue, 12-TM chloride channel essential for airway and gut epithelial secretion. The most common CF mutation, F508del (70% of CF alleles), deletes a single phenylalanine in NBD1 that is critical for domain packing. The mutant protein folds at <5% efficiency; the misfolded fraction is recognised by Hsp70/Hdj2 and RMA1, ubiquitinated, and degraded by ERAD. The functional CFTR that does reach the plasma membrane is slightly unstable but gates normally.

The triumph of the last fifteen years: small-molecule correctors that stabilise nascent CFTR folding. VX-809 (lumacaftor), VX-661 (tezacaftor), and VX-445 (elexacaftor) bind distinct sites on CFTR and improve folding yield. Triple therapy Trikafta (2019), combining VX-445 + VX-661 + the potentiator VX-770 (ivacaftor), restores CFTR function to ~50% of normal in F508del homozygotes and has transformed CF prognosis from a disease of life expectancy ~40 years to, projected, normal life expectancy.

The CF story is the proof-of-concept for the broader class of proteostasis therapeutics: drugs that fix misfolding upstream of functional loss.

2. α₁-Antitrypsin Deficiency

α₁-antitrypsin (A1AT) is a serum serpin synthesised in hepatocytes and secreted to inhibit neutrophil elastase. The common pathological Z mutation (Glu342Lys) promotes intramolecular polymerisation within the ER: A1AT monomers insert their reactive-centre loop into the A sheet of a neighbouring monomer, forming chains of covalent polymers that accumulate as hepatic inclusions.

The disease is thus dual-pathology: hepatic injury from polymer accumulation (cirrhosis, HCC) + pulmonary injury from serum deficiency of A1AT (early-onset emphysema). Current therapy: augmentation with purified pooled A1AT; gene therapy (AAV-A1AT) in trials; small-molecule polymer-blockers in preclinical. Fazirsiran (siRNA targeting mutant A1AT mRNA, approved 2024) silences hepatic production — clearing polymer inclusions without restoring pulmonary A1AT, so typically combined with augmentation.

3. Neurodegeneration & the UPR

Chronic UPR activation is observed in post-mortem tissue from Alzheimer’s, Parkinson’s, Huntington’s, and ALS brains. The misfolded proteins at fault (Aβ, α-synuclein, polyQ huntingtin, SOD1/TDP-43/FUS) are largely cytosolic, but ER proteostasis appears to be indirectly compromised: tau and α-synuclein affect ER-Golgi trafficking; polyQ aggregates sequester ER-resident chaperones; ALS SOD1 directly interacts with ERAD machinery.

Therapeutic implications:

• Salubrinal, guanabenz, sephin1: inhibitors of eIF2α phosphatase GADD34 that sustain ISR. Initial promise in ALS; clinical trials (sephin1/IFB-088) in neuropathy and multiple sclerosis.
• ISRIB: eIF2B activator, restores translation under chronic stress. Rescues cognitive function in mouse models of traumatic brain injury, Down syndrome, prion disease (Halliday 2017). Early human studies.
• PERK inhibitors: early-phase trials; pancreatic β-cell toxicity is the limiting issue.

Hereditary spastic paraplegia (HSP): an especially clear ER-architecture disease. SPG3A/atlastin, SPG4/spastin, SPG31/REEP1, SPG72/REEP2 all disrupt ER tubule morphology in long motor-neuron axons. The disease shows that distal degeneration can be a pure consequence of defective organelle shape.

4. Diabetes: the β-cell UPR

Pancreatic β-cells secrete large amounts of insulin under fluctuating glucose signals. The folding load is enormous: each cell produces ~10⁶ insulin molecules per minute after a meal, all requiring disulphide-bond formation. The β-cell runs near its UPR ceiling constitutively. In type-II diabetes, chronic hyperglycaemia and increasing insulin resistance raise synthesis demand until chronic PERK/CHOP signalling triggers β-cell apoptosis — progressive loss of β-cell mass is a defining feature of advancing T2D.

Rare monogenic diabetes forms make the connection explicit: Wolcott-Rallison syndrome (EIF2AK3/PERK loss-of-function) causes early-onset insulin-dependent diabetes; permanent neonatal diabetes is caused by insulin-misfolding mutations (INS C96Y, Akita mouse). Therapeutic UPR modulation in diabetes is a live research area.

5. Cancer: UPR Addiction

Tumour cells operating in hypoxic, acidic, nutrient-poor microenvironments constitutively activate the UPR to survive. The PERK–ATF4 axis upregulates amino-acid synthesis and autophagy; XBP1s expands ER secretion in multiple myeloma and triple-negative breast cancer. This adaptation is also an Achilles heel: pharmacological UPR inhibition selectively kills tumour cells.

Clinical agents in trials: IRE1 RNase inhibitors (MKC-3946, 4μ8C, B-I09) for multiple myeloma; IRE1 kinase inhibitors; PERK inhibitors (GSK2606414; pancreatic toxicity has tempered enthusiasm); ERO1 inhibitors (EN460). Multiple myeloma — the plasma-cell cancer with the highest secretion load of any human malignancy — is the lead indication and has already been transformed by proteasome inhibitors (bortezomib, carfilzomib) that work by overloading an already stressed ER with non-degradable ubiquitin-conjugates.

6. Viral Hijacking

ER is ground zero for enveloped virus replication. Coronaviruses replicate in double-membrane vesicles derived from ER; flaviviruses (dengue, Zika, hepatitis C) use ER-membrane-remodelling viral proteins to induce replication organelles. SARS-CoV-2 ORF3a, ORF8, NSP3/4/6 remodel ER. Viral envelopes are glycosylated in the ER/Golgi. Several viruses directly modulate the UPR: hepatitis C induces XBP1 splicing to boost ER folding capacity while blocking CHOP-mediated apoptosis, establishing a chronic infection-friendly proteostatic state. Anti-UPR drugs are under investigation as broad-spectrum antivirals.

7. Course Synthesis

Seven modules traced the ER from its architecture and translocation mechanism, through folding, quality control, and stress signalling, to lipid and calcium functions, to the diseases that trace to ER dysfunction. The recurring theme: the ER is the cell’s largest homeostatic organ — a single compartment that the cell uses to integrate protein fate, membrane composition, calcium state, and stress signalling. The clinical consequences of its dysregulation span cystic fibrosis, diabetes, neurodegeneration, cancer, and infection. The ER is, accordingly, one of the richest therapeutic targets of the coming decades.